Non Small Cell Lung Carcinoma Clinical Trial
Official title:
Phase II Trial Evaluating Addition of Fulvestrant to Erlotinib in Patients With Stage IIIB/IV NSCLC Who Are Stable on Erlotinib and Exhibit Positivity for Estrogen or Progesterone Receptor
The main purpose of this research study is to see if adding fulvestrant (Faslodex) to erlotinib (Tarceva) is effective in patients with stage IIIb/IV Non-Small Cell Lung Cancer.
Erlotinib is an oral drug which is able to block endothelial growth factor receptor (EGFR).
EGFR stimulates cancer cell growth. Fulvestrant (faslodex) block estrogen hormone from
gaining access to tumor and stimulating the tumor cells to grow. Both of these drugs are
already approved by FDA but have not been studied in this combination.
We will study if the combination of these drugs will delay treatment failure. Lung cancer
tumors in both males and females can be sensitive to estrogen. Only patients whose tumor
expresses the estrogen will be eligible for the trial. Estrogen sensitivity will be tested
on previously removed tumor specimens.
;
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT01229150 -
Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...
|
Phase 2 | |
Completed |
NCT00199758 -
Study of an Early Change of a Chemotherapeutic Doublet Versus Four Cycles of Chemotherapy in Advanced Non Small Cell Lung Cancer
|
Phase 2 | |
Completed |
NCT01999738 -
Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT01941316 -
Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients
|
Phase 1/Phase 2 | |
Completed |
NCT00111839 -
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
|
Phase 2 | |
Completed |
NCT00181532 -
Phase II Study of Celecoxib and Concurrent Radiotherapy in Stage II-III NSCLC
|
Phase 2 | |
Completed |
NCT00890903 -
Non-Interventional Study With Vinorelbine ORAL in Advanced Non-Small Cell Lung Carcinoma(NSCLC) and Metastatic Breast Cancer (MBC)
|
N/A | |
Completed |
NCT00864266 -
Biological Factors Predicting Response to Chemotherapy in Advanced Non Small Cell Lung Cancer
|
N/A | |
Completed |
NCT00635791 -
Phase I Study of Vorinostat and Sorafenib in Advanced Cancer
|
Phase 1 | |
Recruiting |
NCT00727350 -
Protocol for Primary Fractionated Stereotactic Body Radiation Therapy for Stage T1 - T3N0 Non Small Cell Lung Carcinoma.
|
Phase 2 | |
Completed |
NCT01209520 -
Residual Hypermethylation in Early Stage Non-Small Cell Lung Cancer (NSCLC) As Part of Adjuvant Therapy and Preventive Strategy
|
N/A | |
Active, not recruiting |
NCT00759382 -
Prognostic Role of Primary Non Small Cell Lung Carcinoma Standardized F18-FDG Uptake Values (SUV and TLG) Measured With F18-fluorodeoxyglucose Positron Emission Tomography (F18-FDG-PET): a Non Interventional Study.
|
||
Completed |
NCT00087711 -
A Randomized Phase 3 Trial of Pemetrexed and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer
|
Phase 3 | |
Completed |
NCT00252798 -
ZD1839 (Iressaâ„¢) and Concurrent Chemo-Radiation in Patients With Locally Advanced Non Small Cell Lung Cancer
|
Phase 1 | |
Completed |
NCT02938624 -
Anti PD-1 Neo-adjuvant Treatment for NSCLC
|
Phase 1 | |
Terminated |
NCT00661011 -
Lobectomy and Mediastinal Radiochemotherapy in Unresectable Stage III Non-Small Cell Lung Cancer Responding to Induction Chemotherapy
|
Phase 2 | |
Completed |
NCT00608868 -
SELINE: Second-Line Iressa Phase IV Study in NSCLC Patients
|
Phase 4 | |
Terminated |
NCT00234468 -
Iressa vs Placebo as Maintenance Therapy in Locally Advanced NSCLC
|
Phase 3 | |
Completed |
NCT00193921 -
Chemoradiotherapy in Patients With Localised Lung Cancer
|
Phase 2 | |
Completed |
NCT00252746 -
ZD6474 Phase IIa Dose Finding Multicentre Study
|
Phase 2 |